NIDA funds studies on PN6047 from PharmNovo for potential opioid withdrawal treatment
About Us
PharmNovo AB is a clinical-stage pharmaceutical company focused on developing safe and effective drugs for neuropathic pain. In this area, there is currently a lack of sufficient treatments. The company’s drug candidate, PN6047, effectively reduces neuropathic pain and is devoid of abuse potential in animal models. The company also sees clinical potential in other areas: chronic cough and opioid withdrawal syndrome (OWS). PharmNovo, headquartered in Medicon Village in Lund, Sweden, was founded in 2008 by Bengt von Mentzer, who has more than 30 years of experience in drug development and pain research. The team comprises prominent researchers in academia and industry, and the company has an extensive international network of leading experts and advisors. To learn more, visit pharmnovo.com and follow PharmNovo on LinkedIn.